Introduction: From the institution research list, a total of two pharmaceutical and biological companies were surveyed by more than 20 institutions, namely Xiangsheng Medical and New Mileage. Among them, Xiangsheng Medical has been surveyed by 66 institutions in the past 5 trading days, including Northeast Securities, Southwest Securities, Western Securities, Huatai Securities, Huaan Securities, Huachuang Securities, Huaxin Securities, Caitong Securities, China Post Securities, and Sinolink Securities. New Mileage has also received intensive attention from more than 20 institutions. The company received surveys from 62 institutions including Tianfeng Securities, CSC Financial, Citic Securities, Capital Securities, and SDIC Securities on July 4.
In the past 5 trading days (July 1 to July 7), about 197 companies in the two cities were surveyed by institutions, among which 17 were from the pharmaceutical and biological industry, including Xiangsheng Medical, New Mileage, Maipu Medical, Baicheng Pharmaceutical, Lianhuan Pharmaceutical, Shanwaishan, Haier Biomedical, etc.
From the institution research list, a total of two pharmaceutical and biological companies were surveyed by more than 20 institutions, namely Xiangsheng Medical and New Mileage.
Among them, Xiangsheng Medical has been surveyed by 66 institutions in the past 5 trading days, including Northeast Securities, Southwest Securities, Western Securities, Huatai Securities, Huaan Securities, Huachuang Securities, Huaxin Securities, Caitong Securities, China Post Securities, and Sinolink Securities. Xiangsheng Medical, as an enterprise focusing on the R & D, manufacturing and sales of ultrasonic medical imaging equipment, its products cover fields such as ultrasonic medical imaging equipment, accessories and others, and technical service fees. From January to March 2025, Xiangsheng Medical achieved an operating income of 128 million yuan and a net profit attributable to the parent of 41.6145 million yuan, and has always attached importance to shareholder returns, with a cumulative cash distribution of 464 million yuan after going public.
During the institution research activities, Xiangsheng Medical introduced the company’s newly released “Breast Artificial Intelligence Ultrasound Robot” system, which is mainly aimed at breast cancer. In the design link, this technology, on the basis of the company’s developed breast artificial intelligence screening system, adds an original integrated design including a touch screen, an electric examination bed, a six-degree-of-freedom robotic arm, automatic transmission of ultrasound images, AI-assisted film reading, etc. Combined with an intelligent information system that quickly identifies patient characteristics and an image cloud platform-assisted diagnosis technology, it can realize large-scale scanning and data tracking management of patients.
Regarding the company’s AI technology layout in the obstetrics direction, Xiangsheng Medical said that the company has currently released an intelligent solution covering the entire pregnancy period based on relevant domestic and foreign industry standards. The system can automatically track the fetal position, and support real-time automatic acquisition of standard sections, automatic identification of fetal growth indicators, automatic measurement of development parameters and other systematic quantitative identification results, intelligently recommend the best measurement frame, and automatically generate a fetal examination report, significantly improving the screening accuracy and work efficiency. The above-mentioned mature obstetric ultrasound technology has been widely installed in the company’s obstetric ultrasound product line and is welcomed by users at home and abroad.
New Mileage has also received intensive attention from more than 20 institutions. The company received surveys from 62 institutions including Tianfeng Securities, CSC Financial, Citic Securities, Capital Securities, and SDIC Securities on July 4. New Mileage has developed into a medical and health industry group driven by both medical services and pharmaceutical manufacturing. In the field of medical services, New Mileage creates a “1 + N” innovative service model with a tertiary general hospital as the support, “a comprehensive general hospital + multiple specialized branch hospitals”, and has 3 tertiary hospitals, 14 secondary hospitals, and nearly 10,000 beds, and builds regional medical centers in many places such as Liaoning and Henan. In the field of pharmaceutical manufacturing, with the “Duyiwei” brand as the core, it has a series of Chinese patent medicines and consumer products, forming a whole industry chain cluster of traditional Chinese medicine, and is committed to building a pharmaceutical group integrating the industry chain, supply chain, pharmaceutical manufacturing, and consumption.
Under the current background of relatively pressured industry, the company said that it will improve the hospital’s income and profit levels by promoting the improvement of the hospital’s grade, optimize the disease type structure and the clinical diagnosis and treatment path of medical insurance, strengthen the hospital’s discipline construction to improve the hospital’s ability to admit difficult and severe cases and increase the hospital’s CMI value, give play to the advantages of private hospitals to provide differentiated special medical services (such as high-end physical examinations, special services, etc.) to increase non-medical insurance income and other packages of measures, reduce costs and increase efficiency, and do a good job in the refined operation and management of the existing business. At the same time, actively promote the injection of high-quality assets by the controlling shareholder to contribute increment for the company’s development.
